The Emirates Drug Establishment approved Lipfendra for adults with elevated low-density lipoprotein cholesterol, making the United Arab Emirates the second country worldwide to authorize the treatment, according to a press release issued by the regulatory body. Taken orally once daily, the medication targets LDL-C, which remains one of the primary risk factors for cardiovascular disease. The drug is intended to be used alongside a balanced diet and regular physical activity as part of a personalized healthcare plan.
Expanding Treatment Options for High Cholesterol
According to the Emirates Drug Establishment, the newly authorized oral medication provides an additional therapeutic choice for adults who require medical intervention beyond lifestyle modifications alone. Cardiovascular disease risk management often demands multi-layered approaches. The approval aligns with evidence-based medical practice standards and aims to elevate the overall quality of pharmaceutical care available within the country.
Regulatory Efficiency and Innovation Access
Securing this authorization places the UAE as only the second nation globally to clear the medication for patient use. According to the Emirates Drug Establishment, this milestone highlights the efficiency of the national regulatory framework. It also demonstrates an institutional commitment to accelerating patient access to innovative pharmaceutical treatments.
Did you know? Elevated low-density lipoprotein cholesterol is commonly referred to as “bad” cholesterol because it contributes to plaque buildup in the arteries.
Public Health Recommendations
Health authorities continue to emphasize foundational wellness habits alongside pharmaceutical care. According to the Emirates Drug Establishment, individuals dealing with high cholesterol should maintain a balanced diet and engage in regular physical activity. Patients are urged to consult healthcare professionals to properly assess their clinical conditions and determine appropriate treatment pathways designed to lower cardiovascular risks.
Frequently Asked Questions
What is Lipfendra?
Lipfendra is an oral medication taken once daily that is indicated for the treatment of adults with elevated low-density lipoprotein cholesterol, including certain inherited conditions.
How many countries have authorized this treatment?
According to the Emirates Drug Establishment, the UAE is the second country in the world to authorize the treatment.
What else is required while taking this medication?
The medication is designed to be used alongside a balanced diet and regular physical activity as part of a treatment plan determined by a healthcare professional.
Explore more healthcare and pharmaceutical developments or subscribe to our newsletter for the latest regulatory updates.
Worth a look